$ATRA 🕒 ср, 5 авг. 2020 г., 23:12:03 MSK Atara Biotherapeutics reports Q2 EPS ($1.14), consensus ($1.18) Reports net cash used in operating activities was $56.6M, as compared to $54.6M for the same period in 2019. Pascal Touchon, President and CEO of Atara, said, "We remain on track to initiate a BLA submission for tab-cel for patients with EBV+ PTLD by the end of 2020, despite the COVID-19 outbreak. During the quarter we also reported positive ATA188 clinical data in progressive multiple sclerosis at EAN, successfully completed a follow-on financing, made key executive and board hires, and progressed our CAR T programs closer to the clinic."